Low-dose isotretinoin versus β-carotene to prevent oral carcinogenesis: Long-term follow-up

Journal of the National Cancer Institute

Volumn 89, Issue 3, 1997, Pages 257-258

  Papadimitrakopoulou, Vali A ^a   Hong, Waun K ^a   Lee, Jin S ^a   Martin, Jack W ^a   Lee, J Jack ^a   Batsakis, John G ^a   Lippman, Scott M ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CAROTENE; ISOTRETINOIN;

ARTICLE; CANCER PREVENTION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; LEUKOPLAKIA; MAJOR CLINICAL STUDY; MOUTH CANCER;

EID: 0031015942     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.3.257     Document Type: Article

References (14)

1. Lippman SM, Batsakis JG, Toth BB, Weber RS, Lee JJ, Martin JW, et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 1993;328:15-20.
2. Hong WK, Endicott J, Itri L, Doos W, Batsakis JG, Bell R, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986;315:1501-5.
3. Silverman S Jr, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 1984;53:563-8.
4. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;323:795-801.
5. Yokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328:184-94.
6. Lippman SM, Lee JS, Lotan R, Hittelman W, Wargovich MJ, Hong WK. Biomarkers as intermediate end points in chemoprevention trials. J Natl Cancer Inst 1990;82:555-60.
7. Schatzkin A, Freedman LS, Schiffman MH, Dawsey SM. Validation of intermediate end points in cancer research. J Natl Cancer Inst 1990;82:1746-52.
8. Hong WK, Lippman SM, Hittelman WN, Lotan R. Retinoid chemoprevention of aerodigestive cancer: from basic research to the clinic. Clin Cancer Res 1995;1:677-86.
9. Lee JS, Kim SY, Hong WK, Lippman SM, Ro JY, Gay ML, et al. Detection of chromosomal polysomy in oral leukoplakia, a premalignant lesion. J Natl Cancer Inst 1993;85: 1951-4.
10. Lotan R, Xu XC, Lippman SM, Ro JY, Lee JS, Lee JJ, et al. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 1995;332:1405-10.
11. Xu XC, Zile MH, Lippman SM, Lee JS, Lee JJ, Hong WK, et al. Anti-retinoic acid (RA) antibody binding to human premalignant oral lesions, which occurs less frequently than binding to normal tissue, increases after 13-cis-RA treatment in vivo and is related to RA receptor beta expression. Cancer Res 1995; 55:5507-11.
12. Lippman SM, Shin DM, Lee JJ, Batsakis JG, Lotan R, Tainsky MA, et al. p53 and retinoid chemoprevention of oral carcinogenesis. Cancer Res 1995;5:16-9.
13. Mao L, Lee JS, Fan YH, Ro JY, Batsakis JG, Lippman SM, et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996;2: 682-5.
14. Mao L, El-Naggar AK, Fan YH, Lee JS, Lippman SM, Kayser S, et al. Telomerase activity in the pathogenesis of head and neck squamous cell carcinoma. Cancer Res 1996;56:5600-4.